Julio Garcia-Aguilar

Chief Attending Surgeon, Colorectal Service

Memorial Sloan Kettering Cancer Center

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Julio Garcia-Aguilar is the Chief Attending Surgeon of the Colorectal Service at Memorial Sloan Kettering Cancer Center in the United States. His research focuses on colorectal cancer, with recent publications addressing early-onset versus average-onset colorectal cancers, organ preservation strategies following neoadjuvant therapy, and outcomes related to various surgical approaches for rectal cancer. Additionally, he explores the implications of treatment strategies and genetic profiles on disease-free survival in colorectal cancer patients.

Articles (10)

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (1)

Simon Bach

University of Birmingham

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Julio Garcia-Aguilar

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer.

A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers.

Neoadjuvant short-course radiotherapy with consolidation chemotherapy for locally advanced rectal cancer: a systematic review and meta-analysis.

Type of recurrence is associated with disease-free survival after salvage surgery for locally recurrent rectal cancer.

Watch-and-wait Management for Rectal Cancer After Clinical Complete Response to Neoadjuvant Therapy.

Chemoradiation and Local Excision versus Total Mesorectal Excision for T2N0 Rectal Cancer: Comparison of Short- and Long-Term Outcomes from Two Prospective Studies.

A Coordinated Clinical Center for Young Onset Colorectal Cancer.

A SMAD4-modulated gene profile predicts disease-free survival in stage II and III colorectal cancer.

Non Surgical Treatment in Patients With Advanced Rectal Cancer.

Anorectal Mucosal Melanoma in the Era of Immune Checkpoint Inhibition: Should We Change Our Surgical Management Paradigm?

Collaborators (1)

Simon Bach

Make your next move.